ARP‐1 and H929 cells, seeded at a density of 2 × 105 cells/well in 6‐well plates, were treated with/without SM (5 μM) for 24 h. Apoptotic cells were quantified using a fluorescence‐activated cell sorter (FACS) Vantage SE flow cytometer (Beckman, CA, USA) after staining with Annexin V‐FITC/PI staining kit (Vazyme Biotech Co., Ltd, Nanjing, China).
Primary BM‐MNCs, isolated from the bone marrow of newly diagnosed MM patients, were treated with/without SM (5 μM) and/or BTZ (5 nM) for 24 h. After incubation with conjugated antibody CD138‐PE (Beckman Coulter Immunotech, Marseille, France) for 15 min, the percentage of CD138+ cells was analysed under a FACS Vantage SE flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Primary BM‐MNCs, isolated from the bone marrow of newly diagnosed MM patients, were treated with/without SM (5 μM) and/or BTZ (5 nM) for 24 h. After incubation with conjugated antibody CD138‐PE (Beckman Coulter Immunotech, Marseille, France) for 15 min, the percentage of CD138+ cells was analysed under a FACS Vantage SE flow cytometer (Beckman Coulter, Fullerton, CA, USA).